Lynkuet Access Program Aims to Help Women Save on Neurokinin-Targeted Therapy

This content was independently produced by Pharmacy Times in partnership with Bayer Healthcare.

At The Menopause Society (TMS) 2025 meeting in Orlando, Florida, JoAnn Pinkerton, MD, Professor of Obstetrics and Gynecology at the University of Virginia, discussed the importance of pharmacist involvement in supporting access to emerging neurokinin-targeted therapies such as Lynkuet. She explained that Bayer has partnered with Blink Rx, a digital pharmacy service, to launch the Lynkuet Access, Savings, and Support (LASS) program, which enables commercially insured women to pay as little as $25 per month.

Pharmacy Times: How quickly did patients begin to experience relief, and were improvements sustained throughout the study duration?

JoAnn Pinkerton, MD: I think the most exciting finding, as the PI for the study and when looking at the overall study data, was that elinzanetant reduced the frequency of moderate to severe hot flushes as early as week one. This was a secondary endpoint in both OASIS 1 and OASIS 2. To put that in perspective, hormone therapy might take four to six weeks to show improvement, whereas they were able to demonstrate significance at week one. Obviously, individual results may vary, but it’s an important finding.

Pharmacy Times: How could pharmacists be involved in supporting patients prescribed elinzanetant once available?

Pinkerton: So we need pharmacists’ help. Pharmacists need to understand these neurokinin-targeted therapies and the potential insurance challenges that may arise. Bayer has partnered with Blink Rx, a digital pharmacy service, to provide the Lynkuet Access, Savings, and Support (LASS) program. This initiative helps women access Lynkuet, and through the program, commercially insured women may be eligible to pay as little as $25 per month for Lynkuet. Women can visit lynkuet.com to learn how they can save on the medication.

This is especially important because, with fezolinetant (Veozah), many insurance plans required patients to try two other therapies before they could move on to fezolinetant—creating a significant barrier. Bayer wanted to stay ahead of this issue and make Lynkuet more easily accessible, particularly for pharmacists who play a key role in patient support.